See more : Apollo Medical Holdings, Inc. (AMEH) Income Statement Analysis – Financial Results
Complete financial analysis of Perspective Therapeutics, Inc. (CATX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perspective Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Pirelli & C. S.p.A. (PIRC.MI) Income Statement Analysis – Financial Results
- Talenom Oyj (0RQI.L) Income Statement Analysis – Financial Results
- Birdie Win Corporation (BRWC) Income Statement Analysis – Financial Results
- China Datang Corporation Renewable Power Co., Limited (1798.HK) Income Statement Analysis – Financial Results
- Brascan Gold Inc. (BRCGF) Income Statement Analysis – Financial Results
Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 7.10M | 10.80M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.85M | 8.26M | 7.82M | 6.79M |
| Cost of Revenue | 0.00 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.68M | 7.46M | 6.99M | 6.42M |
| Gross Profit | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838.00K | 129.15K | 167.39K | -196.47K | 150.18K | 703.20K | 1.16M | 725.80K | -353.33K | -151.43K | -54.60K | -1.82M | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 795.61K | 822.28K | 367.89K |
| Gross Profit Ratio | 100.00% | 23.00% | 42.76% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.30% | -630.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.84% | 9.63% | 10.52% | 5.42% |
| Research & Development | 21.31M | 2.60M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965.00K | 528.05K | 614.77K | 668.80K | 627.11K | 730.58K | 465.33K | 340.96K | 958.67K | 1.36M | 1.35M | 450.43K | 137.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.97M | 10.87M | 6.62M | 4.69M | 4.57M | 4.17M | 4.17M | 3.92M | 3.79M | 2.40M | 2.49M | 2.29M | 2.36M | 2.42M | 2.44M | 2.79M | 7.29M | 8.30M | 4.92M | 0.00 | 30.00K | 9.10K | 19.02K | 7.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.00K | 3.23M | 2.80M | 2.44M | 2.98M | 2.68M | 2.66M | 2.31M | 1.35M | 1.49M | 1.23M | 1.30M | 1.22M | 1.23M | 1.95M | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | -20.91K | 9.93K | -11.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.30M | 4.92M | 2.57M | 9.10K | 19.02K | 7.58K | 7.58K | 0.00 | 15.53K | 221.88K | 1.11M | 2.59M | 1.24M | 1.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -73.00K | 2.00K | 0.00 | -48.00K | -456.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.99K | 15.57K | 0.00 | 207.30K | 942.00 | 317.97K | 316.74K | 406.92K |
| Operating Expenses | 42.38M | 17.43M | 12.01M | 8.56M | 8.60M | 8.33M | 8.57M | 7.15M | 5.21M | 4.50M | 4.39M | 4.22M | 4.30M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 1.43M | 2.91M | 1.65M | 1.54M |
| Cost & Expenses | 42.38M | 22.90M | 18.19M | 13.49M | 13.16M | 12.59M | 12.65M | 11.07M | 9.85M | 8.94M | 8.81M | 8.59M | 8.67M | 8.20M | 9.29M | 11.89M | 15.96M | 15.44M | 9.19M | -4.18M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 8.11M | 10.37M | 8.64M | 7.96M |
| Interest Income | 934.00K | 1.12M | 119.00K | 59.00K | 30.00K | 108.00K | 29.00K | 118.00K | 218.15K | 282.75K | 12.11K | 664.00 | 747.00 | 3.38K | 11.43K | 111.05K | 0.00 | 0.00 | 0.00 | 2.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 84.00K | 0.00 | 119.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 950.00 | 2.21K | 883.00 | 7.00 | 61.68K | 216.61K | 36.39K | 75.31K | 274.00K | 0.00 | 1.02M | 167.49K | 0.00 | 2.10K | 41.01K | 51.50K | 0.00 | 0.00 | -12.44K | 0.00 | 163.27K | 66.96K | 108.63K |
| Depreciation & Amortization | 981.00K | 344.00K | 248.00K | 9.00K | 147.00K | -24.00K | 80.00K | 68.00K | 470.85K | 576.38K | 685.40K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 0.00 | 84.85K | -41.01K | -51.50K | 250.68K | -51.50K | 942.00 | 317.97K | 316.74K | 407.42K | 308.83K |
| EBITDA | -39.96M | -14.84M | -7.39M | -3.43M | -3.48M | -5.30M | -6.70M | -6.19M | -4.39M | -4.05M | -3.89M | -3.33M | -2.92M | -2.07M | -3.01M | -5.54M | -7.47M | -8.98M | -6.15M | -3.96M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -234.32K | 13.87K | -2.69M | -436.43K | -1.78M |
| EBITDA Ratio | -2,786.61% | -208.87% | -68.47% | -34.10% | -35.91% | -72.49% | -113.12% | -129.99% | -92.11% | -87.99% | -92.22% | -73.53% | -57.60% | -39.53% | -56.98% | -102.21% | -104.32% | -156.58% | -308.60% | -1,962.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | -32.56% | -5.58% | -26.22% |
| Operating Income | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.60M | -2.96M | -4.01M | -6.47M | -8.80M | -9.70M | -7.20M | -3.98M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.83K | -260.71K | -2.11M | -827.94K | -1.17M |
| Operating Income Ratio | -2,855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1,974.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.32% | -25.55% | -10.59% | -17.21% |
| Total Other Income/Expenses | 835.00K | 512.00K | 119.00K | 50.00K | 30.00K | 134.00K | 29.00K | 27.00K | 154.00K | 374.61K | -1.38M | 210.00K | 170.00K | 334.00K | 0.00 | 274.00K | -274.00K | 0.00 | -385.51K | -285.99K | -2.10K | -2.10K | -41.01K | -51.50K | 0.00 | 0.00 | 12.44K | 43.40K | 895.74K | 15.91K | 920.60K |
| Income Before Tax | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0.00 | -6.20M | -9.08M | 0.00 | -8.22M | -4.27M | -11.20K | -60.03K | -59.08K | -59.08K | 0.00 | 0.00 | -3.09K | -423.98K | -2.15M | -936.57K | -435.09K |
| Income Before Tax Ratio | -2,796.79% | -206.50% | -67.36% | -33.69% | -35.60% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.60% | -54.25% | 0.00% | -114.37% | -126.79% | 0.00% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.40% | -26.03% | -11.98% | -6.41% |
| Income Tax Expense | -2.65M | 0.00 | -119.00K | -199.00K | -177.00K | -294.00K | -29.00K | -145.00K | -371.20K | -655.14K | 1.37M | -210.66K | -109.07K | -120.78K | 24.96K | -309.74K | -245.21K | -94.68K | 1.02M | 0.00 | -86.96K | -84.85K | 41.01K | 51.50K | -250.68K | 51.50K | -942.00 | 2.10K | 2.00K | 2.60K | 2.50K |
| Net Income | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | 75.76K | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M | -939.17K | -437.59K |
| Net Income Ratio | -3,243.24% | -206.50% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.80% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -26.06% | -12.01% | -6.45% |
| EPS | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| EPS Diluted | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| Weighted Avg Shares Out | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
| Weighted Avg Shares Out (Dil) | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT
Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022
Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT
Isoray, Inc. (ISR) CEO Lori Woods on Q2 2022 Results - Earnings Call Transcript
Isoray, Inc. (ISR) CEO Lori Woods on Q2 2022 Results - Earnings Call Transcript
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022
Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT
Isoray, Inc. (ISR) CEO Lori Woods on Q1 2022 Results - Earnings Call Transcript
Isoray, Inc. (ISR) CEO Lori Woods on Q1 2022 Results - Earnings Call Transcript
IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -0.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021
Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray's Cesium-131
RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray's Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131...
Source: https://incomestatements.info
Category: Stock Reports